Hematopoietic stem cell‐  and  induced pluripotent stem  cell‐derived  CAR‐NK  cells as reliable cell‐based therapy solutions | Zendy

Arias Jonathan | Zendy; Yu Jingwei | Zendy; Varshney Mukesh | Zendy; Inzunza Jose | Zendy; Nalvarte Ivan | Zendy

Open Access

Hematopoietic stem cell‐ and induced pluripotent stem cell‐derived CAR‐NK cells as reliable cell‐based therapy solutions

Author(s) -

Arias Jonathan,

Yu Jingwei,

Varshney Mukesh,

Inzunza Jose,

Nalvarte Ivan

Publication year - 2021

Publication title -

stem cells translational medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.781

H-Index - 71

eISSN - 2157-6580

pISSN - 2157-6564

DOI - 10.1002/sctm.20-0459

Subject(s) - chimeric antigen receptor , induced pluripotent stem cell , stem cell , haematopoiesis , cell therapy , hematopoietic stem cell , biology , cancer research , microbiology and biotechnology , immunology , immunotherapy , embryonic stem cell , immune system , biochemistry , gene

Hematopoietic stem cell‐ (HSC) and induced pluripotent stem (iPS) cell‐derived natural killer (NK) cells containing engineered functions, such as chimeric antigen receptors (CAR), offer great promise for the treatment of seemingly incurable oncological malignancies. Today, some of the main challenges of CAR cell‐based therapeutics are the long manufacturing time and safety of the cell sources used. Additional challenges include avoiding graft vs host disease (GVHD) and cytokine release syndrome (CRS). Here, we show compelling evidence for the use of NK cell therapeutics as a reliable off‐the‐shelf option, as they address key issues. Furthermore, we highlight how iPS cells and directed differentiation toward HSC and NK cells address industrial scalability and safety.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research